There is one clinical trial.
We aim to investigate whether the use of Continuous Positive Airway Pressure using a Helmet device (Helmet CPAP) will increase the number of days alive and free of ventilator within 28 days compared to the use of a High Flow Nasal Cannula (HFNC) in patients admitted to Helsingborg Hospital, Sweden, suffering from COVID-19 and an acute hypoxic respiratory failure.
Description: Number of days alive and free of mechanical ventilation within 28 days. Patients who die within 28 days will be counted as 0 VFD. Time in ventilator will be counted in hours and rounded to whole days.Measure: Ventilator-Free Days (VFD) Time: 28 days
Description: Peripheral oxygen saturation divided by fraction of inspired oxygenMeasure: SpO2/FiO2-ratio Time: 1 hour after randomisation
Description: Visual scale (1-10)Measure: Patient comfort Time: 24 hours after randomisation
Description: Min 0, Max 1Measure: Frequency of endotracheal intubation Time: 28 days
Description: Defined as pCO2 > 6 kPa in a venous blood gas. Min 0, Max ∞Measure: Frequency of carbon dioxide rebreathing Time: 28 days
Description: All-cause mortality. (180 days endpoint not in primary publication)Measure: Days alive within Time: 28 days and 180 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports